Greenwich LifeSciences (NASDAQ:GLSI) Earns “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Greenwich LifeSciences (NASDAQ:GLSI) in a research report report published on Wednesday morning, Benzinga reports. They currently have a $36.00 price objective on the stock. HC Wainwright also issued estimates for Greenwich LifeSciences’ Q4 2024 earnings at ($0.17) EPS, FY2024 earnings at ($0.75) EPS, Q1 2025 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.17) EPS and FY2025 earnings at ($0.70) EPS.

Greenwich LifeSciences Stock Performance

Greenwich LifeSciences stock opened at $13.40 on Wednesday. The firm has a market cap of $172.59 million, a price-to-earnings ratio of -18.61 and a beta of 1.55. Greenwich LifeSciences has a 1 year low of $7.58 and a 1 year high of $21.44. The firm’s 50 day moving average price is $15.28 and its two-hundred day moving average price is $12.54.

Greenwich LifeSciences (NASDAQ:GLSI) last announced its earnings results on Monday, April 15th. The company reported ($0.21) earnings per share (EPS) for the quarter. As a group, equities analysts predict that Greenwich LifeSciences will post -0.76 EPS for the current fiscal year.

Insider Activity

In other news, CEO Snehal Patel acquired 1,500 shares of the firm’s stock in a transaction that occurred on Wednesday, March 20th. The stock was purchased at an average price of $17.68 per share, with a total value of $26,520.00. Following the purchase, the chief executive officer now owns 5,345,277 shares of the company’s stock, valued at approximately $94,504,497.36. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have bought 11,100 shares of company stock worth $187,133 over the last 90 days. 52.86% of the stock is owned by company insiders.

Hedge Funds Weigh In On Greenwich LifeSciences

A hedge fund recently raised its stake in Greenwich LifeSciences stock. Vanguard Group Inc. increased its stake in shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) by 0.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 223,102 shares of the company’s stock after purchasing an additional 1,420 shares during the quarter. Vanguard Group Inc. owned approximately 1.73% of Greenwich LifeSciences worth $4,449,000 as of its most recent filing with the SEC. Institutional investors own 4.16% of the company’s stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.